MX360411B - Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos. - Google Patents

Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos.

Info

Publication number
MX360411B
MX360411B MX2015000335A MX2015000335A MX360411B MX 360411 B MX360411 B MX 360411B MX 2015000335 A MX2015000335 A MX 2015000335A MX 2015000335 A MX2015000335 A MX 2015000335A MX 360411 B MX360411 B MX 360411B
Authority
MX
Mexico
Prior art keywords
thiosulphate
lactobacillus
potentiate
order
pathogen effect
Prior art date
Application number
MX2015000335A
Other languages
English (en)
Other versions
MX2015000335A (es
Inventor
Adrien Nivoliez
Original Assignee
Probionov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probionov filed Critical Probionov
Publication of MX2015000335A publication Critical patent/MX2015000335A/es
Publication of MX360411B publication Critical patent/MX360411B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere al uso de tiosulfato para potenciar el efecto anti-patogénico de bacterias lactobacilos; el tiosulfato se encuentra en una cantidad de por lo menos 100 mg para 107 a 1010 unidades formadoras de colonias de lactobacilos; la invención se refiere también a una composición farmacéutica que incluye por lo menos 100 mg de tiosulfato por gramo, en combinación con una cepa Lactobacillus crispatus y a su uso en el tratamiento de infecciones urogenitales tales como vaginosis, candidiasis e infecciones del tracto urinario.
MX2015000335A 2012-07-09 2013-07-09 Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos. MX360411B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1256570A FR2992861B1 (fr) 2012-07-09 2012-07-09 Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
PCT/EP2013/064451 WO2014009349A1 (fr) 2012-07-09 2013-07-09 Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles

Publications (2)

Publication Number Publication Date
MX2015000335A MX2015000335A (es) 2015-07-14
MX360411B true MX360411B (es) 2018-10-30

Family

ID=46826800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000335A MX360411B (es) 2012-07-09 2013-07-09 Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos.

Country Status (16)

Country Link
US (3) US20150139969A1 (es)
EP (1) EP2869825B1 (es)
KR (1) KR101972198B1 (es)
CN (2) CN112999240A (es)
AU (1) AU2013289241A1 (es)
BR (1) BR112014033013A2 (es)
CA (1) CA2877666C (es)
ES (1) ES2604880T3 (es)
FR (1) FR2992861B1 (es)
IN (1) IN2014DN11238A (es)
MX (1) MX360411B (es)
PL (1) PL2869825T3 (es)
RU (1) RU2667122C2 (es)
SA (1) SA113340702B1 (es)
TW (1) TW201414481A (es)
WO (1) WO2014009349A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113564075A (zh) * 2015-06-29 2021-10-29 辉凌制药公司 用于治疗例如细菌性阴道病的鼠李糖乳杆菌细菌
LU92820B1 (fr) * 2015-09-08 2017-03-20 Vesale Pharma International Sa Composition comprenant au moins une bactérie probiotique et destinée à être utilisée pour le traitement de mycoses buccales
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN110799198A (zh) * 2016-11-30 2020-02-14 普罗生物瑞士股份公司 用于稳定阴道液的酸度和氧化还原状态的基于合适的生化组合物的泌尿生殖器医疗设备制剂
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US691972A (en) * 1901-07-29 1902-01-28 F W Rueckheim & Brother Knockdown paper box.
FR1426226A (fr) * 1964-11-20 1966-01-28 Ct De Lyophilisation Pharma Perfectionnements à la conservation des germes microbiens et en particulier des bacilles lactiques par lyophilisation
DK242083D0 (da) 1983-05-27 1983-05-27 Hansens Chr Bio Syst Vaginalkapsler
ZA942302B (en) 1993-12-03 1995-09-29 Lafor Lab Ltd Viracidal bactericidal and spermicidal vaginal suppository
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
EP0956858B1 (en) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
WO2000035465A2 (en) 1998-12-11 2000-06-22 Urex Biotech Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
DE60229169D1 (de) * 2002-03-13 2008-11-13 Matsushita Electric Ind Co Ltd Kühlvorrichtung
JP4315831B2 (ja) * 2004-02-17 2009-08-19 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP4411181B2 (ja) * 2004-10-22 2010-02-10 キヤノン株式会社 画像形成装置
WO2006045347A1 (en) 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
NZ560257A (en) * 2005-01-05 2010-10-29 Chr Hansen Holding As Use of compounds involved in biosynthesis of nucleic acids to increase yield of bacterial culture
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
ITMI20061912A1 (it) 2006-10-04 2008-04-05 S I I T Srl Composizioni farmaceutiche topiche vaginali
CN101033455A (zh) * 2007-02-06 2007-09-12 中国农业科学院北京畜牧兽医研究所 一种低酸发酵加工用植物乳杆菌专用菌株及其发酵剂的制备方法
EP2211640A2 (en) 2007-09-21 2010-08-04 Kerry Group Services International Limited A probiotic composition
FR2933617B1 (fr) 2008-07-10 2010-09-17 Alliospharma Compositions visant a favoriser le developpement et la croissance d'une microflore vaginale benefique
CN107047934A (zh) * 2008-09-17 2017-08-18 拜尔作物科学有限合伙公司 利用枯草芽孢杆菌菌株以增强动物健康的方法
US8329447B2 (en) * 2008-12-12 2012-12-11 Osel, Inc. Strain of Lactobacillus crispatus
EP2206506A1 (en) * 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
CN102438628A (zh) 2009-05-22 2012-05-02 拜耳医药股份有限公司 包含至少一种雌激素和/或至少一种孕激素和至少一种益生菌菌株的供口服给药的药物
CN101919917A (zh) * 2009-06-11 2010-12-22 张博 心脑肾康丸中成药
AU2010270605B2 (en) * 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
ES2388478T3 (es) 2009-12-02 2012-10-15 Bettina Heil Supositorio para la administración rectal, vaginal o uretral que contiene un probiótico, un antibiótico y un ácido graso insaturado no esterificado
EP2428214A1 (en) * 2010-09-14 2012-03-14 HSO Health Care GmbH Compositions for the vaginal and oral administration of lactobacillus and uses thereof
CN102676429B (zh) * 2012-05-11 2013-06-12 刘锋 一种耐高糖高酸的乳酸杆菌
CN103074270A (zh) * 2012-11-15 2013-05-01 上海交大昂立股份有限公司 一种卷曲乳杆菌及其应用

Also Published As

Publication number Publication date
ES2604880T3 (es) 2017-03-09
BR112014033013A2 (pt) 2017-06-27
US20150139969A1 (en) 2015-05-21
KR20150029737A (ko) 2015-03-18
SA113340702B1 (ar) 2015-10-14
US11202799B2 (en) 2021-12-21
TW201414481A (zh) 2014-04-16
FR2992861B1 (fr) 2014-10-17
CA2877666C (fr) 2020-07-14
RU2667122C2 (ru) 2018-09-14
CA2877666A1 (fr) 2014-01-16
MX2015000335A (es) 2015-07-14
US20180360874A1 (en) 2018-12-20
US20220062330A1 (en) 2022-03-03
KR101972198B1 (ko) 2019-04-24
EP2869825B1 (fr) 2016-08-24
CN112999240A (zh) 2021-06-22
CN104519892A (zh) 2015-04-15
FR2992861A1 (fr) 2014-01-10
AU2013289241A1 (en) 2015-01-29
IN2014DN11238A (es) 2015-10-02
EP2869825A1 (fr) 2015-05-13
WO2014009349A1 (fr) 2014-01-16
PL2869825T3 (pl) 2017-04-28
RU2015103115A (ru) 2016-08-27

Similar Documents

Publication Publication Date Title
IN2012DN01638A (es)
GB2511993A (en) Prebiotic formulations and methods of use
SG10201901259RA (en) Prebiotic formulations and methods of use
WO2011110918A8 (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX360411B (es) Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos.
MX345762B (es) Compuestos antiinfecciosos.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
UA100551C2 (en) Synbiotic mixture
UA115520C2 (uk) Дієтична або фармацевтична композиція на основі лактобацил для вагінального або перорального введення
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
WO2012138570A3 (en) Modulating bacterial mam polypeptides in pathogenic disease
MX2013007737A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres.
MX342947B (es) Tratamiento de diabetes tipo 2.
EP2575833A4 (en) THERAPEUTIC AMOUNTS AND USES THEREOF
MX2013007735A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres cronico.
MX2011012071A (es) Prevencion y tratamiento de diarrea alergica.
IN2012DN01414A (es)
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
MY168952A (en) Fe (iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
MY170190A (en) Use of a fermented soy extract as a prebiotic composition

Legal Events

Date Code Title Description
FG Grant or registration